Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • (S)-Mephenytoin: Gold-Standard CYP2C19 Substrate for Drug...

    2025-11-15

    (S)-Mephenytoin: Gold-Standard CYP2C19 Substrate for Drug Metabolism

    Executive Summary: (S)-Mephenytoin is a crystalline anticonvulsive drug primarily metabolized by cytochrome P450 isoform CYP2C19, serving as a definitive substrate for enzyme activity assays (APExBIO). Its usage enables rigorous benchmarking of in vitro human intestinal models, including hiPSC-derived organoids, for pharmacokinetic research (Saito et al., 2025). The compound exhibits a well-defined kinetic profile, with a Km of 1.25 mM and Vmax values between 0.8–1.25 nmol/min/nmol P450 in the presence of cytochrome b5 (APExBIO). Its metabolic fate is sensitive to CYP2C19 polymorphism, making it a reference probe in precision drug metabolism studies (Related Article). Stable storage, high purity (98%), and solubility in ethanol, DMSO, and DMF facilitate robust assay design (APExBIO).

    Biological Rationale

    The small intestine is a key site for absorption and first-pass metabolism of orally administered drugs (Saito et al., 2025). Cytochrome P450 (CYP) enzymes, especially CYP2C19, mediate oxidative drug metabolism, influencing systemic drug levels and efficacy. Genetic polymorphisms in CYP2C19 can profoundly affect individual drug responses. Traditional models, such as animal studies and Caco-2 cell assays, often fail to recapitulate human-specific metabolic diversity (Saito et al., 2025). Human induced pluripotent stem cell (hiPSC)-derived intestinal organoids now provide a more physiological context for assessing drug metabolism, absorption, and transporter interactions.

    Mechanism of Action of (S)-Mephenytoin

    (S)-Mephenytoin (chemical name: (5S)-5-ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione) acts as a selective substrate for CYP2C19, also known as mephenytoin 4-hydroxylase. The enzyme catalyzes two principal reactions: N-demethylation and 4-hydroxylation of the aromatic ring. In vitro, CYP2C19-mediated metabolism of (S)-Mephenytoin is enhanced by cytochrome b5. The kinetic parameters under optimized conditions are: Km = 1.25 mM and Vmax = 0.8–1.25 nmol 4-hydroxy product/min/nmol P450 at controlled temperature and buffer (pH 7.4, 37°C) (APExBIO).

    The metabolic profile of (S)-Mephenytoin provides a sensitive assay for CYP2C19 activity and its inhibition or induction by other compounds. Since CYP2C19 polymorphisms alter (S)-Mephenytoin metabolism, the substrate is widely used to phenotype or genotype patient and donor samples (Related Article).

    Evidence & Benchmarks

    • (S)-Mephenytoin is primarily metabolized by CYP2C19 via 4-hydroxylation and N-demethylation, enabling direct measurement of enzyme activity (Saito et al., 2025).
    • In vitro assays with human liver microsomes and recombinant CYP2C19 confirm (S)-Mephenytoin's selectivity as a substrate (Km = 1.25 mM; Vmax = 0.8–1.25 nmol/min/nmol P450, presence of cytochrome b5) (APExBIO).
    • hiPSC-derived intestinal organoids recapitulate native enterocyte CYP2C19 expression and activity, enabling reliable metabolism studies with (S)-Mephenytoin (Saito et al., 2025).
    • Polymorphisms in the CYP2C19 gene modulate (S)-Mephenytoin hydroxylation rates, supporting its use in pharmacogenetic research (Related Article).
    • (S)-Mephenytoin kinetics provide a standardized benchmark across diverse in vitro and ex vivo drug metabolism models (Related Article).

    This article extends prior coverage by detailing the exact kinetic parameters, model systems, and specific limitations of (S)-Mephenytoin as a CYP2C19 probe, while integrating new evidence from hiPSC-derived organoid platforms (Prior Article).

    Applications, Limits & Misconceptions

    (S)-Mephenytoin is indispensable for:

    • Validating CYP2C19 activity in human-relevant in vitro models, including hiPSC-derived intestinal organoids.
    • Pharmacokinetic studies of anticonvulsive drug metabolism and drug-drug interaction screening.
    • Pharmacogenetic research into CYP2C19 polymorphisms.
    • Benchmarking oxidative drug metabolism across laboratories.

    It is not intended for diagnostic or therapeutic use in humans (APExBIO).

    Common Pitfalls or Misconceptions

    • (S)-Mephenytoin does not comprehensively assess all cytochrome P450 isoform activities; it is selective for CYP2C19.
    • Results from non-human or cancer-derived cell lines may not accurately reflect human intestinal CYP2C19 metabolism (Saito et al., 2025).
    • Long-term storage of (S)-Mephenytoin solutions is discouraged due to stability concerns; store powder at -20°C and prepare fresh solutions (APExBIO).
    • Assays lacking cytochrome b5 may underestimate CYP2C19 activity due to lower catalytic efficiency.
    • Assay outcomes may be confounded by CYP2C19 inhibitors or inducers present in test systems.

    Workflow Integration & Parameters

    For in vitro CYP2C19 enzyme assays, dissolve (S)-Mephenytoin at up to 25 mg/ml in DMSO, ensuring a final assay solvent concentration below cytotoxic thresholds. Use buffer at pH 7.4, incubate at 37°C, and include cytochrome b5 for optimal activity. The recommended substrate concentration for kinetic assays is 1–2 mM. For storage, keep the solid at -20°C; avoid long-term storage of reconstituted solutions. Shipments should use blue ice to maintain stability (APExBIO).

    Integrating (S)-Mephenytoin with hiPSC-derived intestinal organoids enables precise measurement of CYP2C19 activity under near-physiological conditions, supporting advanced pharmacokinetic and pharmacogenetic workflows. This approach complements and updates previous usage in legacy models, as detailed in (S)-Mephenytoin and the Future of Translational Drug Meta... (which focused on model evolution) and (S)-Mephenytoin: Gold-Standard CYP2C19 Substrate for In V... (which benchmarked substrate specificity).

    Conclusion & Outlook

    (S)-Mephenytoin remains the reference CYP2C19 substrate for in vitro and translational drug metabolism studies. Its compatibility with advanced human organoid models, well-characterized kinetics, and sensitivity to genetic polymorphism support its continued utility in precision pharmacology. As hiPSC-derived systems become the new standard for human-relevant pharmacokinetics, (S)-Mephenytoin—available from APExBIO as product C3414 (product page)—will underpin rigorous, reproducible CYP2C19 assays. For further reading on bridging preclinical and clinical drug metabolism with (S)-Mephenytoin, see (S)-Mephenytoin in Precision CYP2C19 Metabolism.